KRYS Stock Risk & Deep Value Analysis

Krystal Biotech Inc

Healthcare • Biotechnology

DVR Score

9.0

out of 10

Hidden Gem

The Bottom Line on KRYS

We analyzed Krystal Biotech Inc using our deep value framework. Sign in to see our full verdict and DVR Score.

We ran KRYS through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.

Updated Mar 30, 2026•Run Fresh Analysis →•

Get notified when KRYS moves

Same alert types as Telegram — presets or custom thresholds in your 🔔 feed.

📈KRYS Performance Overview3yr weekly

📊

Unlock KRYS Performance Chart

See 3 years of price history, quarterly revenue trends, and DVR score changes

Weekly adjusted close · Quarterly revenue & EPS · DVR score history

KRYS Stock Risk Analysis

Overall Risk

Moderate

Financial Risk

Medium

Market Risk

Medium

About Krystal Biotech Inc (KRYS)

Sector

Healthcare

Industry

Biotechnology

Market Cap Category

mid

KRYS Deep Value Analysis

Krystal Biotech maintains its strong '10x potential' trajectory. Vyjuvek's continued robust commercial performance for DEB provides a solid financial base, validating execution. The proprietary STAR-D platform, particularly the AATD program, shows accelerated progress with pivotal clinical readouts anticipated to significantly expand the Total Addressable Market. The leadership's proven ability to navigate regulatory pathways and successfully commercialize gene therapy reinforces confidence. With expanding competitive advantages from their validated platform, internal manufacturing, and clear catalysts on the horizon, KRYS remains exceptionally well-positioned for substantial, multi-faceted growth and potential market disruption, justifying a consistent high score.

KRYS Research Sources

Research sources

No external source links for this analysis yet. Run a fresh analysis to capture SEC filings and financial news articles we used.

For educational context only. Not financial advice.

KRYS Red Flags & Warning Signs

⚠
Negative or inconclusive AATD clinical trial results
⚠
Slower-than-expected Vyjuvek commercial ramp or competitor entry
⚠
Regulatory hurdles or unexpected safety concerns for pipeline candidates

Unlock KRYS Red Flags & Risk Warnings

Premium members see every risk event we found.

📈

Unlock the full report

Create a free account to see the DVR score, risk flags, and AI analysis.

🔥 New Member Exclusive

Unlock everything for $47/yr

$79/yrSave 41%

✓ Catalysts, bull case, moat & red flags
✓ Unlimited stock analyses + alerts
✓ Full database, search & portfolio (50 stocks)

Get Premium — $47/yr

7-day money back · Cancel anytime

KRYS Competitive Moat Analysis

Moat Rating

Narrow

Moat Trend

Expanding

Moat Sources

3 Identified

Intangible Assets/IPSwitching CostsEfficient Scale

The moat is durable due to patented gene therapy vectors (STAR-D platform), an established regulatory precedent with Vyjuvek, and proprietary manufacturing. These factors create significant barriers to entry for competitors in their target indications.

KRYS Competitive Moat Analysis

Premium unlocks moat rating, sources & durability.

KRYS Catalysts & Growth Drivers

Near-Term (0-6 months)

•Q1 2026 Earnings Report (estimated early May 2026)
•Continued Vyjuvek commercial uptake and physician adoption updates
•Phase 3 'TRANSPARENT' trial updates for AATD (Alpha-1 Antitrypsin Deficiency)

Medium-Term (6-18 months)

•Pivotal clinical data readout for AATD program (2027)
•Potential regulatory filing for AATD (2027-2028)
•Advancement of additional pipeline candidates (e.g., CF, rare dermatological conditions)

Long-Term (18+ months)

•AATD market penetration and expansion beyond DEB
•STAR-D platform validation for multiple indications, establishing a broad gene therapy franchise
•Strategic partnerships leveraging proprietary delivery platform for larger indications

Catalysts & Growth Drivers

KRYS Bull Case: What Could Go Right

✓
Acceleration in AATD trial enrollment or positive interim data readouts.
✓
Expansion of Vyjuvek into new geographies or age groups.
✓
Partnership announcements for pipeline assets beyond core indications.

Bull Case Analysis

📊 Explore More Stock Analysis

Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.

Analyze Any Stock →View Top 100 Deep Value Stocks →

FAQ

What is the DVR Score for Krystal Biotech Inc (KRYS)?

As of March 30, 2026, Krystal Biotech Inc has a DVR Score of 9.0 out of 10, placing it in the "Hidden Gem" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.

What ticker symbol does Krystal Biotech Inc use?

KRYS is the ticker symbol for Krystal Biotech Inc. The company trades on the NMS.

What is the risk level for KRYS stock?

Our analysis rates Krystal Biotech Inc's overall risk as Moderate. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.

How often is the KRYS DVR analysis updated?

Our AI-powered analysis of Krystal Biotech Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on March 30, 2026.

Important Disclaimer – Not Financial Advice

Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.

All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.